NZ523805A - Oncolytic virus - Google Patents

Oncolytic virus

Info

Publication number
NZ523805A
NZ523805A NZ523805A NZ52380500A NZ523805A NZ 523805 A NZ523805 A NZ 523805A NZ 523805 A NZ523805 A NZ 523805A NZ 52380500 A NZ52380500 A NZ 52380500A NZ 523805 A NZ523805 A NZ 523805A
Authority
NZ
New Zealand
Prior art keywords
vsv
cells
virus
pkr
interferon
Prior art date
Application number
NZ523805A
Other languages
English (en)
Original Assignee
Pro Virus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Virus Inc filed Critical Pro Virus Inc
Publication of NZ523805A publication Critical patent/NZ523805A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NZ523805A 1999-09-17 2000-09-18 Oncolytic virus NZ523805A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
NZ523805A true NZ523805A (en) 2004-09-24

Family

ID=23573018

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ523805A NZ523805A (en) 1999-09-17 2000-09-18 Oncolytic virus
NZ534306A NZ534306A (en) 1999-09-17 2000-09-18 Method of purifying an oncolytic virus
NZ534307A NZ534307A (en) 1999-09-17 2000-09-18 Use and detection of an oncolytic virus
NZ517573A NZ517573A (en) 1999-09-17 2000-09-18 Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV)

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ534306A NZ534306A (en) 1999-09-17 2000-09-18 Method of purifying an oncolytic virus
NZ534307A NZ534307A (en) 1999-09-17 2000-09-18 Use and detection of an oncolytic virus
NZ517573A NZ517573A (en) 1999-09-17 2000-09-18 Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV)

Country Status (13)

Country Link
EP (2) EP1716858B9 (enExample)
JP (1) JP5060694B2 (enExample)
CN (1) CN1289098C (enExample)
AT (2) ATE418341T1 (enExample)
AU (1) AU782402B2 (enExample)
CA (1) CA2386920C (enExample)
DE (2) DE60041210D1 (enExample)
ES (2) ES2260057T3 (enExample)
HK (1) HK1044708B (enExample)
IL (2) IL148621A0 (enExample)
MX (1) MXPA02002772A (enExample)
NZ (4) NZ523805A (enExample)
WO (1) WO2001019380A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
CA2412493C (en) 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses
US7122182B2 (en) 2001-05-11 2006-10-17 Wellstat Biologics Corporation Oncolytic virus therapy
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
JP2004537305A (ja) * 2001-07-11 2004-12-16 ユニバーシティー オブ マイアミ 腫瘍細胞の処置のための組換えｖｓｖ
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
DK1606411T3 (da) * 2003-03-27 2009-03-30 Ottawa Health Research Inst Mutant vesikulær stomatitis-vira og anvendelse deraf
CA2568772A1 (en) 2004-06-01 2005-12-15 San Diego State University Foundation Expression system based on recombinant vesicular stomatitis virus synthesizing t7 rna polymerase
ZA200702269B (en) * 2004-08-20 2008-09-25 Viralytics Ltd Methods and compositions for treatment of hematologic cancers
WO2006017914A1 (en) 2004-08-20 2006-02-23 Viralytics Limited Methods and compositions for treatment of hematologic cancers
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int ATTENUATED REOVIRUS
ES2741138T3 (es) 2006-09-15 2020-02-10 Childrens Hospital Of Eastern Ontario Res Institute Inc Rhabdovirus oncolítico de Farmington
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
PE20091104A1 (es) * 2007-12-21 2009-07-18 Wyeth Corp Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo
US10603351B2 (en) 2008-08-21 2020-03-31 Turnstone Limited Partnership Engineered synergistic oncolytic viral symbiosis
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
US9707285B2 (en) 2009-03-16 2017-07-18 Turnstone Limited Partnership Vaccination methods
EP2510088B1 (en) * 2009-12-10 2016-10-05 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
WO2012031137A2 (en) * 2010-09-02 2012-03-08 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
ES2627529T3 (es) 2011-06-08 2017-07-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Composiciones para tratamiento de glioblastoma
WO2013050048A2 (en) 2011-10-07 2013-04-11 Skau Aps Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses
CA2901501C (en) 2013-02-21 2023-03-07 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
EP3906931A3 (en) 2013-04-10 2022-02-23 iSD Immunotech ApS Use of immune suppressive domains as medicaments
EP3008176B1 (en) 2013-06-14 2019-08-07 Turnstone Limited Partnership Compositions and methods for enhancing virus replication
EP2826856B9 (en) * 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
CN107076727B (zh) * 2014-07-21 2019-11-01 诺威尔卢斯德克有限公司 用于确定患者特定突变的致癌指数的方法和系统
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
CN110636853B (zh) 2017-05-19 2024-10-18 佐治亚州立大学研究基金会公司 重组溶瘤病毒
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
EP4446337A3 (en) 2017-09-22 2025-01-08 Centre National de la Recherche Scientifique Mutated glycoprotein of vesicular stomatitis virus
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
WO2022033469A1 (zh) * 2020-08-14 2022-02-17 上海行深生物科技有限公司 重组溶瘤病毒及其构建方法和用途
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
US20240218390A1 (en) 2021-02-26 2024-07-04 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
ES2188593T3 (es) * 1992-03-24 2003-07-01 United Cancer Res Inst Vacuna que contiene un virus vivo.
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
DE69837764T2 (de) * 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
CA2305269C (en) * 1997-10-09 2012-07-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO1999032648A1 (en) * 1997-12-22 1999-07-01 The University Of Tennessee Research Corporation Recombinant rhabdovirus containing a heterologous fusion protein
AU3001799A (en) * 1998-03-12 1999-09-27 Trustees Of The University Of Pennsylvania, The Producer cells for replication selective viruses in the treatment of malignancy
WO1999064570A1 (en) * 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Novel methods and interferon deficient substrates for the propagation of viruses
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤

Also Published As

Publication number Publication date
NZ534306A (en) 2005-12-23
EP1218019A2 (en) 2002-07-03
AU7588200A (en) 2001-04-17
IL148621A (en) 2010-02-17
MXPA02002772A (es) 2004-04-02
JP5060694B2 (ja) 2012-10-31
DE60041210D1 (de) 2009-02-05
WO2001019380A3 (en) 2001-11-22
HK1044708B (en) 2006-10-27
DE60026554T2 (de) 2006-09-28
WO2001019380A2 (en) 2001-03-22
CA2386920A1 (en) 2001-03-22
HK1092713A1 (en) 2007-02-16
EP1716858A2 (en) 2006-11-02
JP2004525855A (ja) 2004-08-26
EP1716858B9 (en) 2009-08-12
CA2386920C (en) 2012-01-24
EP1218019B1 (en) 2006-03-08
NZ534307A (en) 2005-07-29
CN1496268A (zh) 2004-05-12
HK1044708A1 (en) 2002-11-01
ES2320239T3 (es) 2009-05-20
DE60026554D1 (de) 2006-05-04
AU782402B2 (en) 2005-07-28
ATE319460T1 (de) 2006-03-15
EP1716858B1 (en) 2008-12-24
CN1289098C (zh) 2006-12-13
ES2260057T3 (es) 2006-11-01
NZ517573A (en) 2004-02-27
EP1716858A3 (en) 2007-08-15
IL148621A0 (en) 2002-09-12
ATE418341T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
AU782402B2 (en) Oncolytic virus
US8147822B1 (en) Oncolytic virus
EP1032269B1 (en) Treatment of neoplasms with interferon-sensitive, clonal viruses
CN1788088B (zh) 突变的水泡性口炎病毒及其用途
JP2005537802A (ja) ラブドウイルスの組み換え型変異体及びその使用方法
US20030044384A1 (en) Treatment of neoplasms with viruses
NZ550861A (en) Treatment of neoplasms with viruses
Elnosary et al. Unlocking the potential: a specific focus on vesicular stomatitis virus as a promising oncolytic and immunomodulatory agent in cancer therapy
HK1092713B (en) Oncolytic virus
Mani et al. Study on Genetically Engineered Vesicular Stomatitis Virus for the Application of Treating Malignant Diseases using Gene Therapy
Nakhaei et al. Oncolytic virotherapy of cancer with vesicular stomatitis virus
AU2005201079B2 (en) Treatment of neoplasms with viruses
Peeples Newcastle disease virus selectively kills human tumor cells
Cary Assessing an M mutant vesicular stomatitis virus for the treatment of glioblastoma multiforme by determining apoptotic mechanisms and antiviral response

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed